08048036315
Betavas 300mg Good Quality Injection to UK - London | Phoenix Exim | Trusted Exporter

1. General Information

Bevatas 300 mg Injection is a prescription anticancer medicine containing bevacizumab, a monoclonal antibody and vascular endothelial growth factor (VEGF) inhibitor. It is used as part of treatment plans for several types of cancer and is generally administered together with other anticancer medicines when indicated.

Bevatas 300 mg Injection is manufactured in India and is supplied as an intravenous infusion under the supervision of an appropriately qualified healthcare professional. Because bevacizumab can cause serious adverse effects, it should only be used according to an oncologist's prescription and treatment protocol.

Exporter information: Phoenix Exim is presented as a medicine exporter from Nagpur, India, supplying pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, prescription and regulatory requirements.

2. Product Information

  • Brand: Bevatas 300 mg Injection
  • Active ingredient: Bevacizumab
  • Strength: 300 mg/12 mL
  • Dosage form: Solution/concentrate for intravenous infusion
  • Therapeutic category: Anticancer / targeted biological therapy
  • Drug class: VEGF inhibitor
  • Manufacturer: Intas
  • Storage: Refrigerated storage at approximately 2–8°C, according to product information; the cold chain should be maintained.
  • Prescription status: Prescription medicine

The exact presentation, pack size, labeling and regulatory status can vary by market.

3. Uses of Bevatas 300 mg Injection

Bevacizumab is used in combination with other medicines for selected cancer indications. Depending on the approved indication and treatment protocol, bevacizumab may be used for:

  • Metastatic colorectal cancer
  • Certain forms of non-small-cell lung cancer
  • Metastatic renal cell carcinoma
  • Certain cervical cancers
  • Certain ovarian, fallopian tube and primary peritoneal cancers
  • Certain other approved cancer indications

The exact use depends on the patient's cancer type, stage, previous treatment and local regulatory approval. The U.S. prescribing information, for example, includes colorectal, non-squamous non-small-cell lung, renal cell, cervical, ovarian/fallopian tube/primary peritoneal and other specific indications.

4. Benefits of This Medicine

Potential clinical benefits of bevacizumab-based treatment include:

  • Helps inhibit the formation of new blood vessels that supply tumors.
  • Can slow tumor growth in cancers that are responsive to VEGF inhibition.
  • Can be combined with chemotherapy or other approved anticancer therapies.
  • Provides a targeted treatment approach rather than acting solely through conventional cytotoxic chemotherapy.

The benefit depends on the particular cancer, treatment combination and individual patient response. It is not appropriate for every cancer patient.

5. Side Effects of Bevatas 300 mg Injection

Bevacizumab can cause side effects ranging from mild to potentially serious. Important risks include:

  • High blood pressure
  • Bleeding or hemorrhage
  • Protein in the urine and kidney-related complications
  • Blood clots
  • Delayed wound healing
  • Gastrointestinal perforation
  • Infusion-related reactions
  • Arterial or venous thromboembolic events
  • Rare neurological complications such as posterior reversible encephalopathy syndrome
  • Heart-related complications in susceptible patients

The official Avastin prescribing information specifically warns about serious risks including gastrointestinal perforation, surgery/wound-healing complications, hemorrhage, arterial thromboembolic events, hypertension, renal injury/proteinuria and infusion reactions.

6. Common Side Effects

Commonly reported adverse reactions include:

  • Nosebleeds
  • Headache
  • High blood pressure
  • Runny nose
  • Proteinuria
  • Changes in taste
  • Dry skin
  • Bleeding
  • Back pain
  • Tiredness
  • Nausea
  • Mouth soreness or ulcers
  • Constipation or diarrhea
  • Reduced appetite

Not every patient experiences these effects, and their severity can vary.

Patients should immediately contact their treating medical team for severe bleeding, severe abdominal pain, chest pain, difficulty breathing, neurological symptoms, significant swelling or other concerning symptoms.

7. How to Use Bevatas 300 mg Injection

Bevatas 300 mg Injection is not a self-administered medicine.

It is administered by intravenous infusion by a qualified healthcare professional, usually in an oncology or hospital setting.

The dose and treatment interval are determined by the oncologist based on factors such as:

  • Cancer type and treatment indication
  • Body weight or body-surface area, where applicable
  • Other medicines being administered
  • Previous treatment
  • Kidney, blood-pressure and general health status
  • Treatment response and adverse effects

The exact dosage must always follow the prescribing information and the oncologist's treatment plan.

8. How This Medicine Works

Bevacizumab is a VEGF inhibitor. VEGF is a signaling protein that promotes the formation of new blood vessels.

Tumors can use newly formed blood vessels to obtain oxygen and nutrients needed for growth. Bevacizumab binds to VEGF and inhibits its activity, thereby reducing VEGF-mediated blood-vessel formation.

By reducing tumor-associated angiogenesis, bevacizumab can help restrict the blood supply supporting tumor growth.

9. Safety Advice

Important safety considerations include:

  • Use only under the supervision of an oncologist or qualified healthcare professional.
  • Do not self-inject or administer this medicine outside an appropriate clinical setting.
  • Blood pressure should be monitored during treatment.
  • Urine protein/kidney function may require monitoring.
  • Inform the doctor about any history of blood clots, bleeding, hypertension, heart problems or kidney problems.
  • Tell the doctor before planned surgery because bevacizumab can interfere with wound healing.
  • Inform the healthcare team about all medicines and supplements being taken.
  • Patients should discuss pregnancy and contraception with their healthcare professional because bevacizumab can pose reproductive risks.
  • Breastfeeding is generally not recommended during treatment and for the period specified by the prescribing information.
  • Maintain the recommended cold-chain storage conditions and protect the product from inappropriate storage conditions.

Important: This information is for educational and product-description purposes and does not replace the prescribing information or advice from an oncologist.

10. Frequently Asked Questions (FAQs)

Q1. What is Bevatas 300 mg Injection?

Bevatas 300 mg Injection is a prescription anticancer medicine containing bevacizumab, a VEGF-targeting monoclonal antibody.

Q2. What is the composition of Bevatas 300 mg?

It contains bevacizumab 300 mg, with product information commonly describing the presentation as 300 mg/12 mL.

Q3. What is Bevatas 300 mg used for?

It is used as part of treatment protocols for several cancers, including selected colorectal, lung, kidney, cervical and ovarian-related cancers, depending on the approved indication.

Q4. Is Bevatas 300 mg a chemotherapy medicine?

Bevacizumab is generally classified as a targeted biological/anti-VEGF therapy rather than conventional cytotoxic chemotherapy. It is frequently administered in combination with chemotherapy or other anticancer treatments.

Q5. How is Bevatas 300 mg administered?

It is administered by intravenous infusion under medical supervision.

Q6. Does Bevatas 300 mg require refrigeration?

Yes. Product information indicates refrigerated storage around 2–8°C. Proper cold-chain handling is particularly important for biological medicines.

Q7. Can Bevatas 300 mg be used without a prescription?

No. It is a prescription anticancer medicine and should be used only under qualified medical supervision.

Q8. What are the most common side effects?

Common effects can include high blood pressure, nosebleeds, headache, proteinuria, bleeding, tiredness, taste changes and gastrointestinal symptoms.

Q9. Is Bevatas 300 mg the same as Avastin?

Both contain bevacizumab, but Bevatas is a branded biosimilar product while Avastin is the reference/originator product. Biosimilars are highly similar to their reference biologics but should be selected or substituted according to applicable regulatory requirements and medical advice.

Q10. Can Phoenix Exim export Bevatas 300 mg Injection?

Phoenix Exim can provide product and export-related information for international buyers. Importation of prescription oncology medicines is subject to the laws, licensing requirements and regulatory approvals of the destination country.

11. Substitute for Bevatas 300 mg Injection

Because Bevatas contains bevacizumab, possible alternatives may include other approved bevacizumab products or biosimilars, depending on the country and indication.

Examples can include:

  • Avastin — reference/originator bevacizumab
  • MVASI — bevacizumab-awwb
  • Other locally approved bevacizumab biosimilars

For example, MVASI is an FDA-designated biosimilar to Avastin (bevacizumab).

Important: A substitute should not be selected solely on the basis of the same generic name or strength. The treating oncologist/pharmacist should confirm the appropriate product, indication, dosage, route, formulation and regulatory status.

12. SEO Keywords

Primary Keywords

  • Bevatas 300 mg Injection
  • Bevatas 300 mg Injection exporter
  • Bevatas 300 mg Injection supplier
  • Bevatas 300 mg Injection manufacturer
  • Bevatas 300 mg wholesale supplier
  • Bevacizumab 300 mg Injection
  • Bevacizumab 300 mg/12 ml Injection
  • Bevacizumab Injection exporter from India
  • Bevacizumab 300 mg supplier India
  • Bevacizumab oncology medicine supplier

Long-Tail B2B Keywords

  • Buy Bevatas 300 mg Injection from India
  • Bevatas 300 mg Injection exporter from Nagpur India
  • Bevatas 300 mg Injection pharmaceutical exporter India
  • Bevatas 300 mg Injection wholesale supplier India
  • Bevacizumab 300 mg Injection wholesale exporter
  • Bevacizumab 300 mg/12 ml oncology injection supplier
  • Bevacizumab 300 mg Injection international supplier
  • Bevatas 300 mg Injection supplier for hospitals
  • Bevatas 300 mg Injection supplier for distributors
  • Bevatas 300 mg Injection B2B pharmaceutical supplier
  • Bevacizumab oncology injection exporter from India
  • Affordable Bevacizumab 300 mg Injection supplier India
  • Genuine Bevacizumab 300 mg Injection supplier
  • Bevacizumab biosimilar injection exporter India
  • Bevatas 300 mg cold chain pharmaceutical exporter

Country & Market Keywords

  • Bevatas 300 mg Injection exporter to USA
  • Bevatas 300 mg Injection exporter to UK
  • Bevatas 300 mg Injection exporter to Australia
  • Bevatas 300 mg Injection exporter to Canada
  • Bevatas 300 mg Injection exporter to Singapore
  • Bevatas 300 mg Injection exporter to South Korea
  • Bevatas 300 mg Injection exporter to UAE
  • Bevacizumab 300 mg supplier USA
  • Bevacizumab 300 mg supplier UK
  • Bevacizumab 300 mg supplier Australia
  • Bevacizumab 300 mg supplier Canada
  • Bevacizumab 300 mg supplier Singapore
  • Bevacizumab 300 mg supplier South Korea
  • Bevacizumab 300 mg supplier UAE

Phoenix Exim SEO Keywords

  • Phoenix Exim Bevatas 300 mg Injection supplier
  • Phoenix Exim Bevacizumab exporter India
  • Phoenix Exim oncology medicine exporter
  • Phoenix Exim pharmaceutical exporter Nagpur
  • Phoenix Exim Bevacizumab 300 mg supplier
  • Trusted pharma exporter from Nagpur India
  • Indian oncology medicine exporter
  • Pharmaceutical medicine exporter from Nagpur
  • Bevacizumab medicine exporter from India to international markets
  • Oncology injection exporter from India to USA UK Australia Canada Singapore South Korea UAE
Aug 13th, 2026 1:42 PM

Keywords